Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 study of CFZ533 in Graves' disease
2015-005564-41Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iscalimab in Graves' disease, sponsored by Novartis. Primary endpoints: TSH normalization at 12 weeks and Change in total T3 and free T4 at 12 weeks. Started Apr 2016; status: completed.
02
Drugs
iscalimab
03
Conditions
Graves' disease
Beyond the preview
Go deeper on 2015-005564-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005564-41.